Skip to main content

Day: September 3, 2020

Crinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D., to Board of Directors

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Camille L. Bedrosian, M.D. as an independent member of its board of directors. Dr. Bedrosian brings over 25 years of experience leading drug development efforts for rare disease products and building successful medical affairs and clinical development teams.“Dr. Bedrosian’s experience in rare disease drug development will be an asset to Crinetics as we advance our pipeline,” said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics. “Her experience navigating the global regulatory landscape and understanding...

Continue reading

Plus Products Launches New PLUS SLEEP Brand, Extends Portfolio of Best-Selling Cannabis Gummies

SAN MATEO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) — Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) (the “Company” or “PLUS”), a cannabis and hemp branded products company in the U.S., today announced the launch of its new PLUS SLEEP brand into the California adult-use market.Highlights4 key ingredients to promote a well-rounded night of sleep: THC, CBN, CBD, and just a touch of melatonin.All-natural colors and flavors, with only 0.7g of sugar and 5 calories per gummy.2 formulations to offer multiple potential solutions to a wide range of consumers: Sleep Cloudberry, with 5mg of THC, 1mg of CBN, and 1mg of CBD, along with CBNRelief Lychee, with 1mg of THC, 2mg of CBN, and 3mg of CBD.PLUS’s new SLEEP gummies are scientifically formulated with a precise blend of cannabinoids and melatonin intended to help consumers fall asleep quickly...

Continue reading

“Ready to Roll!”: Taat Negotiates Favourable Commercial Production Terms with a North American Tobacco Cigarette Manufacturer

Taat has entered into a production agreement with a commercial-scale manufacturer in North America who also produces cigarettes on a contract basis for global and regional brands of both tobacco and hemp. Under this agreement for manufacturing Beyond Tobacco™ cigarettes, Taat will benefit from favourable pricing on a per-carton basis in comparison to industry averages. In addition to production services, the Manufacturer will also warehouse pallets of Beyond Tobacco™ cigarettes after they are produced and facilitate the shipment of finished product to the Company’s distributors.LAS VEGAS and VANCOUVER, British Columbia, Sept. 03, 2020 (GLOBE NEWSWIRE) — TAAT LIFESTYLE & WELLNESS LTD. (CSE: TAAT) (OTC: TOBAF) (FRANKFURT: 2TP2) (the “Company” or “Taat”) is pleased to announce that it has secured commercial-scale production capacity...

Continue reading

Prosafe SE: Prosafe and Shell agree on 2021 North Sea campaign

Prosafe and Shell U.K. Limited (‘Shell’) have agreed to defer and amend the contract for the Safe Zephyrus to provide accommodation services in support of the Shearwater platform turnaround. The revised firm duration of the contract of 115 days commences in March 2021 although Shell has the option of adding either 30 or 45 days to the front end resulting in an earlier commencement date. Shell retains the option to extend the contract after the firm duration by up to 30 days.

Continue reading

Denbury Resources Pre-Packaged Plan Confirmed By Court

Expects to Emerge from Chapter 11 in Mid-September with Strengthened Balance SheetOperations Continuing in Normal CoursePLANO, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) — Denbury Resources Inc. (OTC Pink: DNRCQ) (“Denbury” or the “Company”) today announced that the United States Bankruptcy Court for the Southern District of Texas (the “Court”) has confirmed its “pre-packaged” plan to restructure the Company’s balance sheet and eliminate Denbury’s $2.1 billion of bond debt (the “Plan”).  The Plan received the overwhelming support of the Company’s stakeholders, receiving high consensus across all voting classes and unanimous acceptance from second lien and convertible noteholders.  The Company expects to successfully complete its financial restructuring and emerge from Chapter 11 in mid-September.Consistent with the previously...

Continue reading

GreenMobility reaches operational profitability as the first electric carsharing brand

                                                                                                                                                                                Company Announcement no. 62 – 2020Copenhagen, September 3th, 2020GreenMobility reaches operational profitability as the first electric carsharing brand  With a profit of DKK 350,000 before tax for August, GreenMobility’s operation in Copenhagen has reached profitability, following breakeven in July, as the first car sharing company operating only electric vehicles. At the same time the company reports record-high number of active customers, despite the airport and many educational institutions still being closed.Delivering profitable electric car sharing is a key milestone for GreenMobility and proof that car sharing is the sustainable mobility choice for the future....

Continue reading

The Movie Studio Selects AdvisoryCloud to Hire New Strategic Advisory Board

FORT LAUDERDALE, Fla., Sept. 03, 2020 (GLOBE NEWSWIRE) — via NetworkWire – The Movie Studio Inc. (OTC: MVES) announces it has retained AdvisoryCloud, the leading platform for advisors, to provide advisory services as well as identify and hire expert advisors for The Movie Studio’s advisory board who can help add value to the company.Each year, AdvisoryCloud connects thousands of qualified executives with advisory board positions at companies that are seeking guidance to overcome pressing business challenges, develop strategic initiatives and achieve long-term goals. The Movie Studio will source advisors through AdvisoryCloud’s network of professional advisors to further progress the company’s current growth objective.“One of the greatest resources available to any company proactively seeking advantages that can help their business...

Continue reading

uniQure to Participate in Multiple Upcoming Industry Conferences in September

LEXINGTON, Mass. and AMSTERDAM, Sept. 03, 2020 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that Matt Kapusta, chief executive officer at uniQure, Maria Cantor, senior vice president of investor relations and communications, and Chiara Russo, associate director of investor relations and communications, will participate in the following upcoming conferences in September:Citi’s 15th Annual BioPharma Virtual Conference, September 9 – 10, 2020 A fireside chat with research analyst Shawn Egan will take place on Wednesday, September 9, 2020 from 9:50 – 10:35 a.m. ET. The live webcast of the chat can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.